IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3929
-0.0062 (-1.55%)
At close: Oct 13, 2025, 4:00 PM EDT
0.3950
+0.0021 (0.53%)
After-hours: Oct 13, 2025, 5:59 PM EDT
IGC Pharma Revenue
IGC Pharma had revenue of $328.00K in the quarter ending June 30, 2025, with 20.59% growth. This brings the company's revenue in the last twelve months to $1.33M, up 24.95% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%.
Revenue (ttm)
$1.33M
Revenue Growth
+24.95%
P/S Ratio
23.78
Revenue / Employee
$18,957
Employees
70
Market Cap
36.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IGC News
- 2 days ago - IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders - Accesswire
- 6 days ago - IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease - Accesswire
- 14 days ago - IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial - Accesswire
- 19 days ago - IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology - Accesswire
- 21 days ago - IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Accesswire
- 4 weeks ago - IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection - Accesswire
- 5 weeks ago - IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada - Accesswire
- 6 weeks ago - IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome - Accesswire